Wire · opportunities
FDA Clears First MRI-Derived AI Software for Assessing Breast Cancer Recurrence Risk
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
The FDA has granted 510(k) clearance to TumorSight Risk, the first AI software using MRI scans alongside clinical and pathology data to estimate five- and 10-year breast cancer recurrence risk for women with HR+, HER2-negative stage I-IIIA breast cancer.
This Wire brief sits within Fusion42's coverage of Digital Health, and 6 sources have reported it between 15 Oct 2026 and 17 Oct 2026.
◆ ◆ The Wire takeaway
You now face a new standard in breast cancer prognosis that blends AI with MRI and clinical data. Rapidly integrating this technology could unlock earlier access to personalised treatment decisions and a competitive edge in oncology care.
◆ Coverage
6 sources · first reported 15 Oct 2026 · latest 17 Oct 2026
◆ Related on Wire
◆ Topics